You are here

What’s the Stem Cells Buzz this Week? - Bioconjugated Carbon Dots, Glioblastoma Stem-Like Cell Fate, Tissue-engineered Vascular Grafts, and MSC Transcriptome Evolution!



The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Enhancing Chondrogenesis via Bioconjugated Carbon Dot-mediated Delivery of siTnfα

Mesenchymal stem cell (MSC)‐based therapy of cartilage defects can be hindered by tumor necrosis factor α (TNFα) mediated chronic inflammation. In the hope of mitigating this inflammation, researchers headed by Maolin He, Jinmin Zhao, and Li Zheng (Guangxi Medical University, Nanning, People's Republic of China) sought to introduce small interfering RNA against TNFα via a bioconjugated carbon dot nanovector. Encouragingly, Liu et al. discovered in their STEM CELLS Translational Medicine article that their approach markedly promoted the chondrogenesis of MSCs and could facilitate stem cell‐based therapy of cartilage defects.

Apoptosis Inhibitor Proteins Determine Glioblastoma Stem-Like Cell Fate

Previous studies from the research team of Aurélie Tchoghandjian (Aix-Marseille Université, France) discovered that the inhibition of apoptosis inhibitor proteins induced a loss of stemness and differentiation of glioblastoma stem cell differentiation by activating nuclear factor‐κB under normoxic conditions. Now, Soubéran et al. report that inhibition of apoptosis inhibitor proteins under hypoxia to decreased glioblastoma stem cell viability by reducing cell proliferation and increasing apoptosis through ATR and TNFα pathways. The authors hope that their findings will provide new insights into the dual mechanism of action of apoptosis inhibitor protein inhibitors that depends on oxygen levels, with relevance to their therapeutic application in tumors. For all the details, head over to STEM CELLS now.

Tissue‐engineered Vascular Graft Patency: A Meta-Analysis

Tissue‐engineered vascular grafts (TEVG) represent a treatment option for patients requiring small-diameter autologous vessels for bypass operations. Now, a team led by Ditte Caroline Andersen (Odense University Hospital/University of Southern Denmark, Denmark) undertook a systematic overview and meta‐analysis of related clinically relevant studies. Overall, Skovrind et al. report that future studies should consider a TEVG design that includes endothelial recellularization and bioreactor preconditioning, and suggest that more standard guidelines for testing and reporting TEVGs in large animals should be considered to enable interstudy comparisons and favor a robust and reproducible outcome as well as clinical translation. For all the details, see STEM CELLS Translational Medicine.

Transcriptome Evolution During Cord Mesenchymal Stem Cell Expansion

The widespread clinical application of mesenchymal stem cells (MSCs) as a therapeutic approach for a range of conditions entails extended in vitro culture and expansion; however, is there a replicative limit to their utility? To answer this, researchers headed by Lorena R. Braid (Aurora BioSolutions Inc., Alberta, Canada) assessed transcriptome evolution during MSC expansion, discovering that early-to-mid passage human umbilical cord‐derived MSCs display minimal transcriptome drift and, therefore, this window represents the optimal time to generate consistent MSC batches for therapeutic applications. After this stage, MSCs accumulate elevated transcriptome variation before signs of replicative exhaustion. For all the small print, make your way to STEM CELLS Translational Medicine now!

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!